Evidence map›Paper›PMID 40268863›Full record

ArticlePharmacological reports : PR2025

Unraveling Poland's unprecedented influenza surge in early 2025: increased viral severity or post-pandemic vulnerability?

Piotr Rzymski, Anna Piekarska, Robert Pleśniak, Dominik Sznajder, Dorota Zarębska-Michaluk, Krzysztof Tomasiewicz, Maciej Piasecki, Monika Pazgan-Simon, Justyna Hlebowicz, Karolina Turzańska and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Piotr RzymskiDepartment of Environmental Medicine, Poznan University of Medical Sciences, Poznań, Poland. rzymskipiotr@ump.edu.pl.
Anna PiekarskaDepartment of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland.
Robert PleśniakUniversity of Rzeszów, Clinical Department of Infectious Diseases and Hepatologic Unit, Medical Center in Łańcut, Łańcut, Poland.
Dominik SznajderDepartment of Infectious and Tropical Diseases and Acquired Immunodeficiency, Pomeranian Medical University, Szczecin, Poland.
Dorota Zarębska-MichalukDepartment of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce, Poland.
Krzysztof TomasiewiczDepartment of Infectious Diseases, Medical University of Lublin, Lublin, Poland.
Maciej PiaseckiDepartment of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland.
Monika Pazgan-SimonDepartment of Infectious Diseases and Hepatology, Regional Specialistic Hospital, Wrocław, Poland.
Justyna HlebowiczDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Białystok, Poland.
Karolina TurzańskaDepartment of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland.
Włodzimierz MazurClinical Department of Infectious Diseases in Chorzów, Medical University of Silesia, Katowice, Poland.
Paweł SkwaraDepartment of Infectious and Tropical Diseases, Jagiellonian University Medical College, Kraków, Poland.
Katarzyna SikorskaDivision of Tropical and Parasitic Diseases, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Gdynia, Poland.
Piotr CzuprynaDepartment of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Białystok, Poland.
Szymon PiaszczyńskiDepartment of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland.
Robert FlisiakDepartment of Infectious Diseases and Hepatology, Medical University of Bialystok, Białystok, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt the end of 2024, Polish infectious disease specialists observed a sharp increase in influenza hospitalizations, raising concerns about potential underlying causes. This study aimed to analyze differences in patient characteristics, disease progression, and outcomes among individuals hospitalized for influenza in January 2025 compared to January 2024.

methodsWe conducted an exploratory retrospective comparative study across leading infectious disease units in Poland, evaluating demographic data, clinical presentations, treatment regimens, and outcomes of hospitalized influenza patients from both periods. Key variables included influenza type, age, sex distribution, symptom profile, oxygen saturation, inflammatory markers, presence of co-infections, and type of treatment.

resultsHospitalizations surged by 630% in January 2025, with in-hospital mortality nearly quadrupling to 10.7%. Despite this, patients from both periods had comparable demographic and clinical admission profiles. Most were treated with oseltamivir (though its use was below 90%), and most required antibiotics for bacterial co-infections. Unsurprisingly, the vast majority of hospitalized patients (97%) and non-survivors (93%) in 2025 were unvaccinated. Among non-survivors in 2025, all were infected with influenza A, were older, had higher rates of chronic peripheral circulatory failure, chronic kidney disease, and immunodeficiency, and exhibited more severe inflammatory responses, lower oxygen saturation, and a higher prevalence of dyspnea.

conclusionThe observed surge likely reflects a post-pandemic phenomenon in a vulnerable, aging, comorbid, and largely unvaccinated population. The findings highlight the urgent need for enhanced influenza vaccination strategies in high-risk groups in Poland, as well as the importance of maintaining continuous antiviral availability throughout the epidemic season. Further research encompassing full-season comparisons and incorporating virological, immunological, and health system factors are warranted to better understand the drivers of such surges and guide future preparedness efforts.

Indexed as

Influenza, HumanAdolescentAdultAgedAged, 80 and overAntiviral AgentsChildCoinfectionFemaleHospitalizationHospital MortalityHumansMaleMiddle AgedOseltamivirPandemicsAntiviral AgentsOseltamivirAntiviral treatmentHospitalizationsInfluenzaOutbreaksSurveillance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.